|
|
Volumn 8, Issue 2, 2009, Pages 93-96
|
|
2008 FDA drug approvals
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALOGLIPTIN;
ALVIMOPAN;
BANZEL;
BENDAMUSTINE;
CERTOLIZUMAB PEGOL;
CINRYZE;
CLEVIDIPINE;
CLEVIPREX;
COMPLEMENT COMPONENT C1S INHIBITOR;
DESVENLAFAXINE;
DIFLUPREDNATE;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
DUREZOL;
ECHOVIST;
ELTROMBOPAG;
ETRAVIRINE;
FESOTERODINE;
FOSPROPOFOL;
HARKOSERIDE;
HEMOSTATIC AGENT;
INSULIN;
LEXISCAN;
LIRAGLUTIDE;
LUSEDRA;
NPLATE;
PRASUGREL;
PROVENGE;
RAPAFLO;
RECOMBINANT HUMAN INSULIN;
REGADENOSON;
RILONACEPT;
ROMIPLOSTIM;
RUFINAMIDE;
SILODOSIN;
TAPENTADOL;
TETRABENAZINE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ACUTE CORONARY SYNDROME;
ANGIONEUROTIC EDEMA;
ARTICLE;
CARDIOVASCULAR DISEASE;
CHOREA;
CHRONIC LYMPHATIC LEUKEMIA;
CORONARY ARTERY THROMBOSIS;
CROHN DISEASE;
DECISION MAKING;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SCREENING;
FAMILIAL COLD AUTOINFLAMMATORY SYNDROME;
FINANCIAL MANAGEMENT;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION;
HYPERTENSION;
INSULIN DEPENDENT DIABETES MELLITUS;
LENNOX GASTAUT SYNDROME;
LICENCE;
LUNG CANCER;
MAJOR DEPRESSION;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OVERACTIVE BLADDER;
PERCUTANEOUS CORONARY INTERVENTION;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROSTATE HYPERTROPHY;
RISK MANAGEMENT;
SEDATION;
THROMBOCYTOPENIA;
UNITED KINGDOM;
UNITED STATES;
BIOLOGICAL PRODUCTS;
DRUG APPROVAL;
PHARMACEUTICAL PREPARATIONS;
UNITED STATES;
|
|
EID: 59349115917
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2813 Document Type: Article |
|
Times cited : (83)
|
|
References (0)
|